Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.
Tesaro is in strong position to win another regulatory victory for its drug Zejula, which could boost its standing in the market for PARP inhibitors to treat…
New stats show diabetes patients who suffer severe hypoglycemia are twice as likely to die. No wonder pharma's touting related data on next-gen meds.
Novo’s combination med Xultophy, key to its growth strategy, can dampen CV risk factors such as LDL cholesterol, a new analysis showed.
Sanofi could push a hypoglycemia risk advantage as it works to build up Toujeo scripts—and fights off biosimilar versions of Lantus.
Stop worrying that Roche's Tecentriq might lose its bladder cancer nod. After talks with the FDA, the drugmaker says that threat has passed.
Bristol-Myers' immunotherapy Opdivo cut the risk of a melanoma recurrence by 35% compared with its sister med Yervoy, a new study found.
A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.
Merck & Co. and Incyte unveiled closely watched data on a one-two punch with Keytruda and the experimental IDO1 inhibitor epacadostat.
Clovis may be the middle child among next-gen ovarian cancer meds, but it’s hoping new data will open the therapy to a wave of new patients.